Valeant Stock

VRX Stock: The Path of Least Resistance Is Geared Toward Higher Prices In January of this year, I wrote a publication titled, "Valeant Stock: 2017, The Year VRX Stock Turns It Around." It's now time to rejoice in this festive season because those words have finally come to…

VRX Stock: A Bull Market Begins with This Price Point A lot of eyes, including my own, are watching the price action in Valeant Pharmaceuticals Intl Inc (NYSE: VRX) stock because after such a fall from grace, many (myself included) have been anticipating that perhaps the worst may be behind…

VRX Stock: One Piece Away from a Bull Market A number of bullish events have transpired since my last update on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock. In that May 17, 2017 update, titled "Valeant Stock Is Slowly Becoming Bullish Once Again," I outlined a number of stock chart…

VRX Stock: Staging an Advance Putting hard-earned dollars into an investment like Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock isn't easy, especially since the stock has been nothing more than a weapon of wealth destruction. In August 2015, VRX stock traded as high as $263.81, and it took less…

Validation and a Couple Wins for VRX Stock  Valeant Pharmaceuticals Intl Inc (NYSE:VRX) must be feeling some measure of validation as the U.S. Securities and Exchange Commission (SEC) has levied a $15.0 million fine at Allergan plc (NYSE:AGN) for failing to disclose news of friendlier bids during a hostile takeover…

Valeant's Sell-Offs to L'Oreal and Sanpower Boosted VRX Stock Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is starting 2017 off on a good note, with VRX stock up over six percent by early afternoon trading on Tuesday. The boost came as a result of several big sales that the company was able to make,…

Hopes for Valeant Are Fading Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is no longer an investable asset, but is instead a trading vehicle for short sellers and those who think new CEO Joseph C. Papa can put VRX stock back on Wall Street's radar. Perhaps the new year can…

VRX Stock: Time for a Comeback Will 2017 be the year that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock finally makes a comeback? Such a question is difficult to answer because the bearish trend toward lower prices has been relentless, and my quest to find a bottom in Valeant stock…

Can VRX Stock Rise Again? Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is down 4.5% on Wednesday as billionaire William Ackman’s Pershing Square Capital Management LP cut its stake in the company and several executives departed. Pershing is the largest investor in VRX stock, although the recent move has put its stake in…

Another Blow for VRX Stock  At this point, it doesn't seem that Valeant Pharmaceuticals Intl Inc (NYSE:VRX, TSE:VRX) could buy good news if it offered half of its VRX stock. The company was down five percent on Monday after the U.S. Food and Drug Administration (FDA) approved a generic version of "Nitropress."…

Is Trump Going to Kill Pharma and Valeant Stocks?  President-elect Donald Trump may not be the friend that the pharmaceutical industry had hoped for. Despite gaining in the early days following his election, the NASDAQ Biotechnology Index is down three percent on Wednesday as Trump vows to reduce drug prices.…

Valeant Pharmaceuticals Intl Inc (NYSE:VRX, TSE:VRX) just cannot catch a break these days. VRX stock is down another 7.5% as a deal to sell off its stomach medication fell through. Japan’s Takeda Pharmaceutical Co Ltd (TYO:4502) was in talks with Valeant to acquire Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) from the company…

Valeant Takes Another Blow  Valeant Pharmaceuticals Intl Inc (NYSE:VRX) can't seem to catch a break. The company dropped another 4.75% today as the embattled pharmaceutical producer was once again downgraded to "Underperform" from "Neutral" by Irina Koffler at Mizuho Securities Co., Ltd., where she believes investors are reaching the end…

VRX Stock: Bottom Fishing Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock made headlines last week when it reported its earnings and, to the dismay of the bulls, earnings were disappointing as Valeant missed on both the top and bottom lines. Valeant management guided lower as they now expect total…

Valeant Stock Could Benefit from Trump Presidency Valeant Pharmaceuticals Intl Inc (TSE:VRX) has made huge losses and huge gains in the span of 24 hours. Valeant stock lost 22% on election day and gained back almost eight percent the day after. What happened? Donald Trump won. A Donald Trump presidency…

What's Pushing VRX Stock Back Up? Valeant Pharmaceuticals Intl Inc (TSE:VRX) sees VRX stock ride a roller coaster as the shares rise eight percent today despite falling 19% just a day before. This sudden rise hardly offsets the pounding that VRX stock has withstood for the past month, dropping 30%…

Why is VRX Stock in Shambles Right Now Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares have plummeted. VRX stock dropped another 19% today, furthering what has already been a brutal 2016 for the company. There's a lot to unpack in the tale of VRX stock. First, the news. Valeant is…

VRX Stock: Potential Bottom Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock is making headlines once again, and investors are trying to stay on top of these new developments. The newswire is causing some serious volatility in VRX stock and on November 1, 2016, Valeant stock surged higher on the…

What Does VRX Stock's Rally Mean?  Valeant Pharmaceuticals Intl Inc (NYSE:VRX) made an impressive recovery today as VRX stock rose 30% despite the ongoing investigation into two of the company’s former executives. Yesterday, VRX stock looked all but dead after falling 12.02% as a result of a fraud investigation…

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock is plummeting on rumors that U.S. prosecutors are building a fraud case against two former company executives. Valeant stock plunged 12.02% after news of the investigation went public. Former CEO J. Michael Pearson and former CFO Howard Schilling could face charges within weeks. (Source:…